AstraZeneca PLC Director/PDMR Shareholding (3828D)

TIDMAZN

RNS Number : 3828D

AstraZeneca PLC

19 February 2020

19 February 2020 07:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demaré, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demaré purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of GBP73.13 per Share.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                          Michel Demaré 
     ----------------------------  ------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status               Non-Executive Director 
     ----------------------------  ------------------------------------- 
 b)   Initial notification          Initial notification 
       /Amendment 
     ----------------------------  ------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                          AstraZeneca PLC 
     ----------------------------  ------------------------------------- 
 b)   LEI                           PY6ZZQWO2IZFZC3IOL08 
     ----------------------------  ------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the            Ordinary Shares of US$0.25 each in 
       financial instrument,         AstraZeneca PLC 
       type of instrument 
 
       Identification code           GB0009895292 
     ----------------------------  ------------------------------------- 
 b)   Nature of the transaction     Share purchase 
     ----------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)          Price(s)      Volume(s) 
                                        GBGBP73.13         700 
                                                    ---------- 
     ----------------------------  ------------------------------------- 
 d)   Aggregated information        Not applicable - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
     ----------------------------  ------------------------------------- 
 e)   Date of the transaction       17 February 2020 
     ----------------------------  ------------------------------------- 
 f)   Place of the transaction      XLON 
     ----------------------------  ------------------------------------- 
 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @ AstraZeneca .

 
 
   Media Relations 
 Gonzalo Viña                                                                         [phone] 
 Rob Skelding                           Oncology                                           [phone] 
 Rebecca Einhorn                        Oncology                                           [phone] 
 Matt Kent                              BioPharmaceuticals                                 [phone] 
 Jennifer Hursit                        Other                                              [phone] 
 Christina Malmberg Hägerstrand    Sweden                                             [phone] 
 Michele Meixell                        US                                                 [phone] 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                                       [phone] 
 Henry Wheeler                          Oncology                                           [phone] 
 Christer Gruvris                       BioPharmaceuticals (cardiovascular; metabolism)    [phone] 
 Nick Stone                             BioPharmaceuticals (respiratory; renal)            [phone] 
 Josie Afolabi                          Other medicines                                    [phone] 
 Craig Marks                            Finance, fixed income                              [phone] 
 Jennifer Kretzmann                     Corporate access, retail investors                 [phone] 
 US toll-free                                                                              [phone] 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHUWSVRRAUUAAR

(END) Dow Jones Newswires

February 19, 2020 02:00 ET (07:00 GMT)